Advancing Immunotherapy with Metabolic Drugs: Towards Improved Melanoma Treatment
Grant Amount: NIS 5.2 Million
About the Project
Immunotherapy revolutionized cancer treatment, leading to durable responses even in the most aggressive cancer types, such as melanoma. Despite this success, more than 50% of melanoma patients do not respond to treatment. Our previous work showed an association between the metabolic state of the melanoma cells and the immunotherapy response. In the current project we aim to increase treatment efficacy by combining immunotherapy with metabolic drugs in vitro, in vivo and in patients. We will then examine the effects on all cell populations in the tumor micro-environment. Through development of single cell proteomics approaches and integration with single cell RNA-seq, we aim to obtain a comprehensive functional view of melanoma response.  
Research Team
Prof. Tamar Geiger
Tel Aviv University, Human Molecular Genetics and Biochemistry
Prof. Neta Erez
Tel Aviv University, Pathology
Prof. Gal Markel
Chaim Sheba Medical Center, Ella Lemelbaum Institute for Immuno-Oncology
More Projects Funded